Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer

J. R. Kroep, E. F. Smit, G. Giaccone, K. Van Der Born, J. H. Beijnen, C. J. Van Groeningen, W. J F Van Der Vijgh, P. E. Postmus, H. M. Pinedo, G. J. Peters

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To compare the pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer (NSCLC). Patients and methods: Twenty-four chemo-naive patients with advanced NSCLC were randomized to receive one of the three regimens. Plasma pharmacokinetics and pharmacologic parameters in mononuclear cells were compared and related to toxicity and efficacy. Results: Pharmacological parameters of gemcitabine and cisplatin were not influenced by the combination with one of the other agents, while the paclitaxel clearance was significantly lower for the combination with cisplatin as compared to gemcitabine (P=0.024). The percentage decrease in platelets was significantly higher for the gemcitabine combinations (P=0.004) and related to the dFdCTP-Cmax (P=0.030). Pharmacologic parameters were not related to response or survival. Conclusions: Gemcitabine and cisplatin pharmacology were not influenced by the combination with one of the other agents, while paclitaxel has a lower clearance in combination with cisplatin as compared to gemcitabine.

Original languageEnglish (US)
Pages (from-to)509-516
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume58
Issue number4
DOIs
StatePublished - Oct 2006
Externally publishedYes

Keywords

  • Cisplatin
  • Gemcitabine
  • Non-small cell lung cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Fingerprint Dive into the research topics of 'Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this